Cosmax (A192820) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
20 Feb, 2026Executive summary
Q1 2025 revenue rose 11.7% year-over-year to KRW 588.6 bn, driven by strong growth in Korea and Southeast Asia, while the US saw a decline.
Operating profit increased 13.0% year-over-year to KRW 51.3 bn, with a record high Q1 operating margin of 8.7%.
Net profit dropped 45.8% year-over-year to KRW 10.6 bn, impacted by non-operating losses and a significant one-off expense.
Financial highlights
Korea sales up 15.0% year-over-year to KRW 362.8 bn; operating profit up 14.0%.
China sales up 3.4% to KRW 162.7 bn; operating profit turned negative.
Indonesia sales up 22.8% to KRW 29.6 bn; Thailand sales up 152.1% to KRW 23.9 bn, both with improved profitability.
US sales down 26.0% to KRW 28.7 bn; net loss narrowed.
Gross profit increased 4.5% year-over-year to KRW 104.8 bn; SG&A costs decreased 3.0%.
Outlook and guidance
US region expects improved performance in the second half as new client sales ramp up.
Continued investment in production capacity in Korea to meet high demand.
Latest events from Cosmax
- Strong revenue and profit growth in 4Q 2025, led by health supplement and holding segments.A192820
Q4 20258 Mar 2026 - Korea and Southeast Asia drove robust profit growth, offsetting China and US weakness.A192820
Q3 202420 Feb 2026 - Q2 2024 delivered double-digit sales and profit growth, driven by Korea and Southeast Asia.A192820
Q2 202420 Feb 2026 - Record Q4 profit growth driven by Korea and Southeast Asia, with net profit turning positive.A192820
Q4 202420 Feb 2026 - Revenue up 1.0% YoY, but net loss widened on one-off costs; BTI outperformed.A192820
Q3 202520 Feb 2026 - Record revenue and profit growth offset by net profit decline from non-operating expenses.A192820
Q2 202512 Aug 2025